Published in J Clin Oncol on June 10, 2006
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano (2009) 2.39
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88
Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol (2009) 1.88
Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer (2009) 1.79
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer (2010) 1.61
Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2008) 1.60
Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res (2011) 1.54
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol (2007) 1.40
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res (2009) 1.35
Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene (2009) 1.32
The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer (2013) 1.30
Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res (2011) 1.27
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.26
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets (2010) 1.25
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res (2009) 1.25
Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia (2008) 1.23
Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia (2008) 1.17
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer (2012) 1.15
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther (2008) 1.15
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res (2012) 1.15
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer (2007) 1.14
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer (2011) 1.10
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst (2014) 1.09
EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol Biol Cell (2008) 1.07
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One (2013) 1.05
Molecular targeted therapies in head and neck cancer--an update of recent developments-. Head Neck Oncol (2010) 1.03
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer (2008) 1.01
Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep (2014) 1.00
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol (2009) 1.00
Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (2007) 1.00
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene (2010) 0.99
Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol (2010) 0.98
A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol (2009) 0.98
Construction of oncogenetic tree models reveals multiple pathways of oral cancer progression. Int J Cancer (2009) 0.97
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer (2007) 0.94
Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene (2010) 0.93
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck (2011) 0.93
High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. Transl Oncol (2010) 0.92
In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice. Int J Nanomedicine (2011) 0.92
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol (2016) 0.91
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2012) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am (2008) 0.91
Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer (2010) 0.91
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther (2011) 0.90
p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene (2007) 0.90
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene (2012) 0.90
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) (2009) 0.90
Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck (2011) 0.89
Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol (2012) 0.88
Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma. Neoplasia (2012) 0.88
Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway. Clin Cancer Res (2011) 0.87
pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther (2012) 0.87
The molecular pathogenesis of head and neck cancer. Cancer Biol Ther (2010) 0.87
Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.86
Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG-The Role of EGFR Signaling and "Lipid Raft". J Oncol (2011) 0.86
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer (2011) 0.86
Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers. Int J Cell Biol (2012) 0.86
Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). PLoS One (2014) 0.86
The current state of head and neck cancer gene therapy. Hum Gene Ther (2009) 0.85
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. Int J Cancer (2012) 0.85
Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck (2012) 0.85
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res (2014) 0.85
Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation. PLoS One (2012) 0.84
Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One (2013) 0.84
Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet (2014) 0.84
A naturally occurring feline model of head and neck squamous cell carcinoma. Patholog Res Int (2013) 0.84
Quantum dot-based nanoprobes for in vivo targeted imaging. Curr Mol Med (2013) 0.83
Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. J Cell Physiol (2012) 0.83
Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One (2013) 0.83
Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma. PLoS One (2015) 0.83
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. BMC Cancer (2016) 0.83
Lentiviral vector-based therapy in head and neck cancer (Review). Oncol Lett (2013) 0.83
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther (2016) 0.82
STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. Mol Cancer Ther (2015) 0.82
Selective Killing Effects of Cold Atmospheric Pressure Plasma with NO Induced Dysfunction of Epidermal Growth Factor Receptor in Oral Squamous Cell Carcinoma. PLoS One (2016) 0.82
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer Chemother Pharmacol (2010) 0.82
Biomolecular markers in cancer of the tongue. J Oncol (2009) 0.82
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol (2014) 0.82
Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am (2013) 0.82
EGF up-regulates miR-31 through the C/EBPβ signal cascade in oral carcinoma. PLoS One (2014) 0.82
High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. Cell Commun Signal (2014) 0.82
Human papillomavirus, p16, and epidermal growth factor receptor biomarkers and CT perfusion values in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol (2013) 0.81
Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck. J Oncol (2012) 0.81
RNA interference-mediated silencing of G protein-coupled receptor 137 inhibits human gastric cancer cell growth. Mol Med Rep (2014) 0.81
Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach. PLoS One (2012) 0.81
Cholinergic transactivation of the EGFR in HaCaT keratinocytes stimulates a flotillin-1 dependent MAPK-mediated transcriptional response. Int J Mol Sci (2015) 0.80
Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5. Virology (2009) 0.80
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. Onco Targets Ther (2009) 0.80
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
The impact of health insurance status on the survival of patients with head and neck cancer. Cancer (2010) 1.58
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 1.56
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA (2007) 1.41
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.39
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res (2011) 1.34
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis (2009) 1.30
Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility. Gastroenterology (2004) 1.28
Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol (2006) 1.25
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis (2010) 1.24
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J (2008) 1.21
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res (2007) 1.20
Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys (2009) 1.17
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17
Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res (2010) 1.17
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol (2008) 1.16
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther (2008) 1.15
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res (2012) 1.15
Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope (2010) 1.14
Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene (2005) 1.13
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol (2009) 1.13
Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther (2008) 1.12
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.12
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) (2010) 1.10
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res (2007) 1.09
Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck (2008) 1.08
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther (2009) 1.08
Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck (2005) 1.07
MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer (2010) 1.07
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol (2009) 1.04
Head and neck cancer: recent advances and new standards of care. J Clin Oncol (2006) 1.02
Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope (2005) 1.02
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Nucleic acid-based approaches to STAT inhibition. JAKSTAT (2012) 1.02
EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther (2012) 1.01
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01
Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res (2008) 1.00
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol (2009) 1.00
Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (2007) 1.00
Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther (2013) 0.99
Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res (2012) 0.99
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res (2014) 0.99
Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head Neck Pathol (2013) 0.97
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol (2011) 0.97
The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res (2013) 0.95
The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol (2011) 0.94
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res (2012) 0.94
Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res (2011) 0.93
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res (2011) 0.93
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy (2012) 0.92
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem (2008) 0.92
Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res (2008) 0.92
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (2012) 0.92
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2013) 0.91
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.90
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res (2012) 0.90
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther (2012) 0.90
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest (2015) 0.90
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol (2006) 0.89
Association of the EGFR intron 1 CA repeat length with lung cancer risk. Mol Carcinog (2007) 0.89
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer (2013) 0.89
Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther (2012) 0.89
Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog (2005) 0.88
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res (2008) 0.87
Prognostic biomarkers in head and neck cancer. Clin Cancer Res (2006) 0.87
Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck (2006) 0.87
The molecular pathogenesis of head and neck cancer. Cancer Biol Ther (2010) 0.87
Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther (2003) 0.87
Childhood passive smoke exposure is associated with adult head and neck cancer. Cancer Epidemiol (2013) 0.86
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest (2015) 0.86
Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark (2010) 0.86
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther (2013) 0.85
Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res (2010) 0.85
Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology (2002) 0.85